| Controlled substance | Drug<br>code                 | Schedule         |
|----------------------|------------------------------|------------------|
| Sufentanil           | 9740<br>9743<br>9780<br>9801 | <br>  <br>  <br> |

The company plans to import the listed controlled substances for distribution for analytical testing purposes. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

#### Marsha Ikner.

Acting Deputy Assistant Administrator.
[FR Doc. 2024–07525 Filed 4–8–24; 8:45 am]

## **DEPARTMENT OF JUSTICE**

# Drug Enforcement Administration [Docket No. DEA-1355]

## Importer of Controlled Substances Application: Lyndra Therapeutics

**AGENCY:** Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

**SUMMARY:** Lyndra Therapeutics has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 9, 2024. Such persons may also file a written request for a hearing on the application on or before May 9, 2024.

Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and follow the online instructions at that site for submitting comments. Upon submission

of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on March 6, 2024, Lyndra Therapeutics, 60 Westview Street, Lexington, Massachusetts 02421–3108, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug<br>code | Schedule |
|----------------------|--------------|----------|
| Methadone            | 9250         | II       |

The company plans to import the above controlled substance for use in preclinical research and human clinical trials. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

## Marsha Ikner,

Acting Deputy Assistant Administrator. [FR Doc. 2024–07529 Filed 4–8–24; 8:45 am]
BILLING CODE P

## **DEPARTMENT OF JUSTICE**

[OMB Number 1123-1NEW]

Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection; Application for Remission of Financial Penalties

**AGENCY:** Office of the Pardon Attorney, Department of Justice. **ACTION:** 60-Day notice.

SUMMARY: The Office of the Pardon Attorney, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

**DATES:** Comments are encouraged and will be accepted for 60 days until June 10, 2024.

FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Kira Gillespie, Deputy Pardon Attorney, Office of the Pardon Attorney, 950 Pennsylvania Avenue NW, Main Justice—RFK Building, Washington, DC 20530; uspardon.attorney@usdoj.gov; 202–616–6070.

**SUPPLEMENTARY INFORMATION:** Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Bureau of Justice Statistics, including whether the information will have practical utility;
- —Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- —Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and